Until recently, many Walgreens Boots Alliance (NASDAQ: WBA) investors were desperately hungry for good news to boost the company’s languishing stock price. On Dec. 10 they got some, in the form of a news report detailing a potential buyout deal. That gave the shares a bit of a bump, but overall, investors remain cautious.
Should they be so guarded, or is this an opportunity to snap up an underappreciated stock at a serious discount?
That Dec. 11 report was published by The Wall Street Journal, which wrote that Walgreens management is in discussions with private equity firm Sycamore Partners to take itself private. Typically, a go-private deal prices the company undergoing the transformation at a premium.
The financial newspaper implied that there is some urgency to these talks. Citing unidentified “people familiar with the matter,” it wrote that the two sides might complete a deal early next year.
Neither Walgreens nor Sycamore has yet officially commented on the article.
Taking itself off the stock market would eliminate the pressure Walgreens’s management surely feels from shareholders, who have seen the value of their holdings wither. Despite the fairly minor price bump from the apparent buyout discussion news, the pharmacy chain operator’s stock has largely been a big downer this year.
Walgreens is currently coping with several challenges to its business and not handling them all that well. It has the problem many other traditional businesses share, in that it’s still a heavily brick-and-mortar operator in an environment where the retail apocalypse continues to claim casualties.
In March, Amazon launched same-day delivery for medications, and several months later, Walmart announced it would pilot a similar service. Having one mighty retailer trying to poach your business is a tough situation; having to contend with a potential two exponentially worsens the problem.
On top of that, the power of pharmacy benefit managers (PBMs) has negatively affected Walgreens’ profit margin. PBMs have quite effectively managed to shave drug prices for both health insurance providers and businesses.
Walgreens has taken steps to rationalize its business, but these feel like a case of too little, too late. In the summer, management announced plans to shut scores of underperforming stores and to reduce its investment in primary-care company VillageMD. Yet it’s not as if these outlets just started to post weak results. The push into the care segment was never particularly well thought out even at the outset.
